Objective. Class 3 semaphorins regulate diverse cellular processes relevant to the pathology of RA, including immune modulation, angiogenesis, apoptosis and invasive cell migration. Therefore, we analysed the potential role of class 3 semaphorins in the pathology of RA.
Introduction
RA is a chronic immune-mediated inflammatory disease marked by persistent synovial inflammation and progressive destruction of joints, leading to disability and loss of quality of life. Synovial hyperplasia, a result of infiltration of immune cells into the joint and the accumulation of synovial stromal fibroblast-like synoviocytes (FLS), is a hallmark of RA [1] . FLS play a key role in the RA pathology, contributing to the perpetuation of inflammation and to the formation of new blood vessels, through the release of pro-inflammatory cytokines, chemokines and pro-angiogenic factors [2] . RA FLS also contribute to joint destruction by releasing MMPs, cathepsins and aggrecanases, which degrade extracellular matrix components and cartilage, as well as the RANK ligand (RANKL), which promotes osteoclast differentiation and erosion of adjacent bone [1, 3] . RA FLS display multiple features resembling those of tumour cells, like anchorage-independent growth, resistance to apoptosis, and elevated expression of proto-oncogenes that promote cellular proliferation. Together, these characteristics drive FLS invasion of surrounding tissue and the degradation of cartilage [36] .
The semaphorin family is a large group of proteins initially described as regulators of neural development. Class 3 semaphorins are secreted proteins defined by their semaphorin (Sema), plexin, semaphorin, integrin (PSI), immunoglobulin-like (Ig) and basic C-terminal domains. Receptors of class 3 semaphorins are comprised of two single-spanning transmembrane proteins, PlexinA members (Plexin A1A4), which contain a signaltransducing motif, and neuropilin (NRP) co-receptors (NRP-1 and -2), which constitute the ligand-binding subunit [79] . In addition to their role in controlling cell migration and axonal growth cone guidance, further studies have shown that class 3 semaphorins regulate other biological processes relevant to pathology in RA, including the control of immune responses, angiogenesis, apoptosis, and cell invasion [79] . Moreover, class 3 semaphorins are associated with the pathogenesis of multiple sclerosis, Alzheimer's disease, myocarditis, atherosclerosis, osteopetrosis and cancer [7, 10, 11] . Some class 3 semaphorins act as tumour suppressors, and their expression is reduced or absent in several cancer types [1215] . The administration or the overexpression of different class 3 semaphorin members like Sema3A, Sema3B and Sema3F reduces tumour progression, through the induction of apoptosis, the impairment of angiogenesis and the inhibition of cell migration and invasion. However, little is known about how class 3 semaphorins might contribute to pathology in RA. Therefore, we investigated the expression, regulation and function of class 3 semaphorins in RA.
Methods
Patients, synovial tissue and RA FLS culture Synovial biopsies were obtained from the inflamed knee, wrist or ankle joints of 14 early DMARD-naïve arthritis patients (disease duration <1 year) by needle arthroscopy as previously described [16] . Upon entry into the study, patients were classified based on established classification criteria for RA [17] , spondyloarthritis [18] or other arthritic diseases, and patients not fulfilling these criteria were classified as undifferentiated arthritis (UA) patients. After 2 years follow-up, patients were classified as having selflimiting or persistent disease, as previously described [19] . FLS were obtained from the inflamed joints of 15 RA patients. Clinical characteristics of all patients are detailed in supplementary Tables S1S3, available at Rheumatology online. All patients supplied written informed consent prior to inclusion in the study, and this study was approved by the medical ethics committee of the Academic Medical Center, University of Amsterdam, The Netherlands.
FLS treatment and stimulation FLS were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and used between passages 5 and 10, and synovial biopsies were stored in liquid nitrogen until processing. FLS were cultured overnight in medium containing 1% fetal bovine serum prior to incubation with cytokines. FLS were stimulated with IL-1b (1 ng/ml, R&D systems), TNF (10 ng/ml, Biosource International) or LPS (1 mg/ml, Sigma). Alternatively, RA FLS were stimulated with Sema3A, Sema3B or Sema3F (100 ng/ml, R&D systems) in the presence or absence of PDGF (10 ng/ml, R&D systems).
Monocyte purification, macrophage differentiation and stimulation Human PBMCs were isolated from healthy volunteer donor blood buffy coats (Sanquin) and from peripheral blood (PB) and SF of RA patients by gradient centrifugation with Lymphoprep (Axis-Shield PoPAS). Monocytes were further isolated by Percoll gradient separation (GE Healthcare). Patient clinical characteristics from whom monocytes or SF were obtained are detailed in supplementary Table S4 , available at Rheumatology online. Monocytes were differentiated into macrophages in Iscove's Modified Dulbecco's Medium (IMDM)/10% fetal bovine serum (FBS) supplemented with 100 mg/ml gentamycin (Invitrogen), in the presence of IFN-g (M1 macrophages, 10 ng/ml, R&D Systems), IL-10 (M2 macrophages, 10 ng/ml, R&D Systems) or 20% SF from RA (RA SF, pooled from five patients) for 7 days.
Statistical analyses
Statistical analysis was performed using SPSS v18.0.2 software (SPSS) and Windows GraphPad Prism 6 (GraphPad Software, Inc.). Potential differences between experimental groups were analysed by a non-parametric, KruskalWallis test or Friedman test, as appropriate. P < 0.05 was considered statistically significant.
Details of material and methods for mRNA expression analysis, immunoblotting, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and proliferation assays, migration and invasion assays, MMP measurement, siRNA transfection, flow cytometry and Rac1 pull-down assays can be found as supplementary data, available at Rheumatology online.
Results
Class 3 semaphorin expression in the synovium of early arthritis patients
We analysed baseline mRNA expression of class 3 semaphorins, the most common class 3 semaphorin receptor, plexin-A1 and the co-receptors NRP-1 and -2 in the synovial tissue of 12 early (disease duration <1 year), DMARD-nä ive arthritis patients. At baseline, four patients were classified as having RA, and eight patients had UA. We observed a significant reduction in Sema3B and Sema3F mRNA expression in patients classified at baseline as having RA compared with those classified as having UA (P < 0.05 and P < 0.01, respectively, Fig. 1A ). We did not observe differences in expression of semaphorin receptors between RA and UA patient groups (Fig. 1B) . As class 3 semaphorins are secreted proteins, we analysed the expression of Sema3B and Sema3F in the SF of 6 RA and 6 UA patients by quantitative immunoblotting. Due to the dimerization of the recombinant proteins, the molecular weight of the recombinant human Sema3B (rhSema3B) and rhSema3F was higher than the molecular weight of Sema3B and Sema3F observed in the SF of the UA and RA patients. Similarly to data found at the mRNA level, the expression of Sema3B was significantly reduced in RA compared with UA patients [8.7 ± 5.2 vs 22.5 ± 5.4 ng/mg, P < 0.05]. Sema3F expression also showed a trend towards a lower expression in RA patients, although differences were not significant [185.3 ± 134.5 vs 270.7 ± 64.1 ng/mg, Fig. 1C and D]. After 2 years' follow-up, seven patients had persistent disease, while five patients had self-limiting disease. At baseline, there was a significant downregulation of Sema3B, Sema3C, Sema3F, Sema3G and NRP-1 mRNA expression in patients with persistent disease compared with in those with self-limiting disease (P-values ranging between <0.05 and <0.01, supplementary Fig. S1 , available at Rheumatology online).
Strong and significant negative correlations were observed between the expression of Sema3B, Sema3F and Sema3G with DAS28, swollen joint count of 28 joints (SJC28) and tender joint count of 28 joints (TJC28) scores ( Fig. 2A) . A significant negative correlation was also observed between the expression of these semaphorins and both ESR and CRP levels ( Fig. 2A and supplementary Fig. S2 , available at Rheumatology online). Sema3F expression negatively correlated with synovial mRNA expression of TNF, and Sema3B and Sema3G with IL-6, TNF and IL-1b (P-values between <0.05 and <0.001, Fig. 2B ). Thus, the expression of a subset of class 3 semaphorins is reduced in the synovium of early arthritis patients with persistent disease after follow-up, and negatively associates with clinical and molecular parameters of disease activity.
Cellular expression of class 3 semaphorins and their regulation in FLS
We next determined the expression of class 3 semaphorins in monocytes, macrophages and FLS, major cellular constituents of RA synovial tissue. We analysed the expression in macrophages differentiated with IFN-g (MÈ IFN-g ) or with IL-10 (MÈ IL-10 ), representative of macrophage phenotypes previously identified in RA synovial tissue [20, 21] . In macrophages derived from healthy donors and differentiated with SF of RA patients, in RA patient PB and SF-derived macrophages differentiated with IFN-f or IL-10, and in RA patient PB monocytes, we found low mRNA expression of Sema3A, Sema3B, Sema3C, Sema3F and Sema3G, while Sema3D and Sema3E were not detected (Fig. 3A) . Expression of Sema3A, Sema3C, Sema3D, Sema3E and Sema3G was low in RA FLS, but Sema3B and Sema3F were expressed at significantly higher levels compared with the other cell populations (P-values ranging between <0.05 and <0.001, Fig. 3A ). Plexin-A1, NRP-1 and NRP-2 were detected in all cell populations analysed, but expression was reduced in monocytes compared with other cell populations. mRNA expression of these receptors was similar between RA FLS and the different macrophage subtypes (supplementary Fig. S3 , available at Rheumatology online).
We next determined possible influences of the inflammatory mediators TNF, IL-1b and LPS on RA FLS class 3 semaphorin expression. Sema3C, Sema3D, Sema3E and Sema3G mRNA expression was not regulated by these agonists, but all three stimuli significantly induced Sema3A mRNA expression (Fig. 3B) . In contrast, mRNA expression of Sema3B and Sema3F was reduced after FLS stimulation (P-values ranging from <0.05 to <0.01, Fig. 3B) . At the protein level, TNF stimulation resulted in a trend, statistically insignificant, towards reduced Sema3B and Sema3F expression. IL-1b or LPS stimulation significantly reduced RA FLS secretion of both semaphorins (P-values ranging between <0.05 and <0.01; Fig. 3C and D). We were unable to detect Sema3A protein, possibly reflecting low mRNA expression and/or Sema3A secretion. Together, these results suggest that in RA synovial tissue, class 3 semaphorins are primarily expressed by FLS, and this expression is regulated by inflammatory mediators.
Class 3 semaphorins regulate ERK and Rac1 activation
To validate the effects of RA FLS treatment with class 3 semaphorins, we assessed the activation status of molecular pathways modulated by class 3 semaphorins [7, 11] . First, we analysed the activation of extracellular signal-regulated kinase (ERK) and protein kinase B (PKB), two protein kinases involved in signalling pathways that regulate cell migration and invasion, in RA FLS treated in the absence or presence of PDGF, a potent agonist of these processes in RA FLS [22] . PDGF induced strong ERK and PKB activation after 15 and 60 min treatment. Sema3A, Sema3B and Sema3F had no effect on PDGFinduced PKB activation. However, Sema3B and Sema3F (1 ng/ml) or lipopolysaccharide (LPS) (1mg/ml). Data is shown as delta C t (ÁC t ) (A) or relative quantity with respect to medium. Bars represent the means and SEM of four to six patients. (C) Representative immunoblot of Sema3B and Sema3F protein expression in FLS stimulated 24 h with TNF (10 ng/ml), IL-1b (1 ng/ml) or LPS (1 mg/ml). (D) Densitometric analysis of Sema3B and Sema3F protein expression. Data is shown as relative expression with respect to tubulin expression. Bars represent the means and SEM of five individual experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, compared with medium. significantly reduced PDGF-induced ERK activation at 60 min (P < 0.05; Fig. 4A and B) . Sema3B and Sema3F also reduced the ERK activation induced by FBS, but had no effect on PKB activity (supplementary Fig. S4 , available at Rheumatology online). We also analysed the effect of class 3 semaphorin stimulation of RA FLS on the activation of Rac1, a Rho GTPase involved in cytoskeleton remodelling and RA FLS cell migration and invasion [7, 11, 23] . PDGF induced a strong and rapid Rac1 activation, which was partially reduced by Sema3A and almost completely abrogated by Sema3B and Sema3F (Fig. 4C and D) .
Class 3 semaphorins modulate the migration and invasive capacity of RA FLS
We next analysed the functional consequences of RA FLS stimulation with Sema3A, Sema3B and Sema3F, the subset of class 3 semaphorin members regulated in these cells after stimulation with inflammatory mediators. Previous studies have demonstrated that class 3 semaphorins can regulate cell viability and proliferation [2426] . However, Sema3A, Sema3B and Sema3F had no effect on FLS cell viability or proliferation (supplementary Fig. S5 , available at Rheumatology online). Next, we determined the possible effects of these semaphorins on RA FLS migration and invasive capacity. Sema3A significantly induced cell migration, while Sema3B and Sema3F reduced RA FLS migration (P < 0.05; Fig. 5A  and supplementary Fig. S6A , available at Rheumatology online). Interestingly, stimulation of FLS with Sema3B or Sema3F in combination with Sema3A reduced cell migration to the same extent as did Sema3B or Sema3F alone, suggesting that the inhibitory effect of Sema3B and # P < 0.05 as compared with medium. *P < 0.05 and ***P < 0.001.
Sema3F on cell migration is predominant over the promigratory effect of Sema3A (supplementary Fig. S6B , available at Rheumatology online). Sema3A alone also induced FLS invasive capacity and significantly enhanced cell invasion induced by FBS and PDGF (P < 0.05). In contrast, Sema3B and 3 F significantly reduced cell invasion induced by FBS and PDGF (P < 0.05; Fig. 5B and supplementary Fig. S7 , available at Rheumatology online). As MMPs play a key role in cell invasion through the degradation of extracellular matrix components, we determined whether Sema3A, Sema3B and Sema3F could regulate RA FLS MMP expression (Fig. 5C ). Sema3A significantly upregulated mRNA expression of MMP-8 and -12 (P < 0.01 and P < 0.05, respectively). Sema3B significantly downregulated mRNA expression of MMP-7 and -9 (P < 0.001 and <0.05, respectively) and showed a trend towards a downregulation of MMP-1 and -2. Sema3F significantly reduced the expression of MMP-9, -12, -14 and -16 (P-values ranging from <0.05 to <0.01) and, similarly to Sema3B, reduced the expression of MMP-1 and -2, although differences were not statistically significant. Stimulation with class 3 semaphorins also regulated other genes implicated in extracellular matrix FIG. 5 Class 3 semaphorins regulate the invasive capacity of RA FLS (A and B) Migration (A) and invasion (B) of RA FLS stimulated with Sema3A, Sema3B or Sema3F (100 ng/ml) in the presence or absence of 10% fetal bovine serum (FBS) or PDGF (10 ng/ml) for 18 and 40 h (migration) or 24 h (invasion). Data is shown as migration or invasion indices and presented as connected dots. *P < 0.05. (C and D) mRNA (C) and protein (D) expression of MMPs and extracellular matrix remodellingrelated genes in RA FLS stimulated with Sema3A, Sema3B or Sema3F (100 ng/ml) for 4 and 24 h. Data is shown as relative quantity with respect to medium. Bars represent the means and SEM of four to six individual experiments. *P < 0.05, **P < 0.01 and ***P < 0.001, compared with medium. remodelling and invasion, as Sema3A upregulated mRNA expression of the adhesion molecule NCAM1, while Sema3B and Sema3F downregulated the expression of CNTN1, CTGF, CLEC3B and CNTN1, CTGF, TSP-3 and NCAM1 (P-values ranging between <0.05 and <0.01, supplementary Fig. S8 and Table S6 , available at Rheumatology online).
To independently confirm our gene expression data, we determined the effect of class 3 semaphorin exposure on protein secretion of a subset of the MMPs modulated at the mRNA level (Fig. 5 and supplementary Table S7 , available at Rheumatology online). Sema3A significantly induced the production of MMP-8 (P < 0.05), but had no effect on the production of MMP-1, -3 and -9. Sema3B and 3 F reduced FLS secretion of MMP-1 and -3 (P-values ranging between <0.05 and <0.001) and had no effect on MMP-8 and -9 production. Together, these results demonstrated that specific class 3 semaphorins regulate FLS invasive capacity, potentially through the modulation of MMP production.
Plexin-A1, NRP-1 and NRP-2 regulate class 3 semaphorininduced FLS migration Class 3 semaphorins bind to different Plexin-A receptors, as well as NRP-1 and -2 co-receptors [8, 9] . To identify the receptors and co-receptors responsible for modulating class 3 semaphorin effects on RA FLS migration and invasive capacity, we silenced Plexin-A1, NRP-1 and NRP-2 expression using siRNA. Silencing efficiency at the level of mRNA and protein was confirmed for Plexin-A1, NRP-2 and NRP-1 (supplementary Fig. S9 , available at Rheumatology online). As observed in previous experiments, Sema3A induced FLS migration, and Sema3B and Sema3F reduced this migration (P-values ranging from <0.05 to <0.001; Fig. 6AC ). Induction of RA FLS migration by each of the class 3 semaphorins was completely abrogated after Plexin-A1 and NRP-2 silencing (P-values ranging from <0.05 to <0.001; Fig. 6A and B) . Silencing NRP-1 expression inhibited Sema3A-induced FLS migration (P < 0.01), but failed to affect Sema3B and Sema3Finduced migration (Fig. 6C) . These data suggest that plexin-A1 and NRP-2 regulate RA FLS migration induced by the class 3 semaphorins analysed in this study, while NRP-1 is specifically involved in Sema3A-induced cell migration.
Discussion
We demonstrated that class 3 semaphorins are differentially expressed in the synovium of early arthritis patients and that their expression is associated with disease persistence and future fulfilment of classification criteria for RA. Previously, Sema3C expression was found to be increased in RA synovial tissue compared with OA synovial tissue, while Sema3A expression is reduced and its exogenous administration reduces disease severity in murine CIA [2729] . Here, we find that altered expression of some of the family members, such as Sema3A, Sema3B and Sema3F, may play an important role in joint destruction, based on their ability to regulate FLS migration and invasive capacities. Importantly, we observed a reduction in the mRNA expression of Sema3B, Sema3C, Sema3F and Sema3G in early arthritis patients with persistent disease after 2 years of follow-up, as well as a reduction in the mRNA and protein levels of Sema3B and Sema3F in patients who fulfilled classification criteria for RA after follow-up. Moreover, Sema3B, Sema3F and Sema3G negatively correlated with parameters of disease activity. These results bear similarities with oncology studies, where Sema3B and Sema3F expression is reduced in different cancer types and is related to tumour cell metastatic and invasive potential [24, 3032] .
Among major cell populations found in inflamed synovial tissue, Sema3B and Sema3F are expressed by RA FLS, but not by RA monocytes/macrophages, and their expression is downregulated after inflammatory stimulation. This may be important in vivo, as we observed in early arthritis patient synovial tissue that mRNA expression of Sema3B, and to a lesser extent Sema3F, negatively correlated with the expression of TNF and IL-1b, cytokines which are present in the synovial compartment of early arthritis patients [2, 33] . Initial inflammatory cues in the early arthritis synovial environment might reduce Sema3B and Sema3F expression, contributing to disease development by blocking a negative regulatory mechanism that would suppress FLS invasive capacity.
Class 3 semaphorins are involved in two interconnected processes contributing to FLS-mediated joint destruction, the regulation of MMP production and the invasive capacity of FLS. In contrast to other cell types [2426, 34] , RA FLS cellular proliferation and viability are not regulated by class 3 semaphorins. This may be related to the high resistance of RA FLS to apoptosis, through mechanisms such as high expression levels of the anti-apoptotic protein FLIP, and elevated activation of the pro-survival PKB pathway [35, 36] . In line with this, the numbers of FLS are similar in early arthritis patients, regardless of whether or not they develop persistent disease or RA [37, 38] .
Interestingly, Sema3A induced FLS migration and invasion, while Sema3B and Sema3F inhibited these processes. Sema3A, Sema3B and Sema3F regulated FLS migration through plexin-A1 and NRP-2, but only Sema3A required NRP-1 for its effects on migration. These findings are in accordance with those of other studies [39] and suggest that the opposite role of Sema3A (compared with Sema3B and Sema3F) is related to the differential utilization of NRP co-receptors. This might account for the differential effects of Sema3A, Sema3B and Sema3F on FLS MMP production, since we observed that PlexinA1 is not involved in the MMP production induced by these semaphorins (data not shown).
We also observed that in RA FLS, as in other cell types [24, 40, 41] , Sema3B and Sema3F inhibited activation of the protein kinase ERK and the small GTPase Rac1. Interestingly, ERK activation is elevated in RA synovial tissue compared with in that of controls, as well as in early arthritis patients who develop erosive RA [42, 43] . Rac1 regulates RA FLS invasiveness in vitro, and its inhibition reduces paw swelling and antibody production in CIA [23, 4447] . Therefore, Sema3B and Sema3F may reduce FLS invasive capacity through the inhibition of these molecular pathways. Modulation of ERK and PKB activity by class 3 semaphorins is probably cell typespecific, as in some cell types PKB activation, but not ERK, is regulated by Sema3B and Sema3F [31, 48] , while in RA FLS, ERK but not PKB is regulated by class 3 semaphorins. The differential effects of Sema3A, Sema3B and Sema3F we observed on RA FLS kinase and GTPase activation, as well as invasive capacity might be attributable to the different co-receptors involved.
In conclusion, our results suggest that administration of Sema3B and Sema3F or the development of agonist antibodies targeting their co-receptor, NRP-2, might protect against progressive joint destruction in RA and therefore could be a potential therapeutic target for the treatment of RA.
